Analyzing Mobileye Global (NASDAQ:MBLY) & Aspire Biopharma (NASDAQ:ASBP)

Aspire Biopharma (NASDAQ:ASBP) and Mobileye Global (NASDAQ:MBLY) are both consumer discretionary companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends and risk.

Analyst Ratings

This is a summary of current ratings and target prices for Aspire Biopharma and Mobileye Global, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aspire Biopharma	1	0	0	0	1.00
Mobileye Global	2	9	10	2	2.52

Mobileye Global has a consensus price target of $12.16, indicating a potential upside of 55.90%. Given Mobileye Global’s stronger consensus rating and higher possible upside, analysts clearly believe Mobileye Global is more favorable than Aspire Biopharma.

Profitability

This table compares Aspire Biopharma and Mobileye Global’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Aspire Biopharma	-11,362.21%	N/A	-177.59%
Mobileye Global	-201.49%	0.70%	0.67%

Volatility and Risk

Aspire Biopharma has a beta of 0.17, suggesting that its share price is 83% less volatile than the S&P 500. Comparatively, Mobileye Global has a beta of 1.22, suggesting that its share price is 22% more volatile than the S&P 500.

Earnings & Valuation

This table compares Aspire Biopharma and Mobileye Global”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aspire Biopharma	$10,000.00	1,190.00	-$24.48 million	($69.62)	-0.12
Mobileye Global	$1.89 billion	3.46	-$392.00 million	($4.99)	-1.56

Aspire Biopharma has higher earnings, but lower revenue than Mobileye Global. Mobileye Global is trading at a lower price-to-earnings ratio than Aspire Biopharma, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

19.2% of Aspire Biopharma shares are held by institutional investors. Comparatively, 13.3% of Mobileye Global shares are held by institutional investors. 5.8% of Aspire Biopharma shares are held by insiders. Comparatively, 10.0% of Mobileye Global shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Mobileye Global beats Aspire Biopharma on 11 of the 15 factors compared between the two stocks.

About Aspire Biopharma

Aspire Biopharma Holdings, Inc., early-stage biopharmaceutical company, engages in developing and marketing of disruptive technology for delivery mechanisms for do no harm drugs in the United States. The company provides Sublingual Aspirin Product, which addresses cardiology emergencies and pain management. It develops formulation for a sublingually administered melatonin sleep-aid product; vitamins D, E, and K; testosterone; and semaglutide, as well as formulations for anti-nausea products, anti-psychotic products, ED drugs, seizure medication, and several other classes of drugs. The company was founded in 2021 and is based in Humacao, Puerto Rico.

About Mobileye Global

Mobileye Global Inc. develops and deploys advanced driver assistance systems (ADAS) and autonomous driving technologies and solutions worldwide. The company operates through Mobileye and Other segments. It offers Driver Assist comprising ADAS and autonomous vehicle solutions that covers safety features, such as real-time detection of road users, geometry, semantics, and markings to provide safety alerts and emergency interventions; Cloud-Enhanced Driver Assist, a solution for drivers with interpretations of a scene in real-time; Mobileye SuperVision Lite, a navigation and assisted driving solution; and Mobileye SuperVision, an operational point-to-point assisted driving navigation solution on various road types and includes cloud-based enhancements, such as road experience management. The company also provides Mobileye Chauffeur, a first-generation solution for eyes-off/hands-off driving with a human driver still in the driver’s seat; Mobileye Drive, a self-driving system comprising of radar and lidar subsystems, as well as collision avoidance systems, including Mobileye 8 Connect for light and medium-duty vehicles, and Mobileye Shield+ for large vehicles. It serves original equipment manufacturers. The company was founded in 1999 and is headquartered in Jerusalem, Israel. Mobileye Global Inc. operates as a subsidiary of Intel Overseas Funding Corporation.